# Dysregulated bile acid metabolism as a novel player in gout progression: emerging therapeutic strategies

**Authors:** Hui Sun, Le Yang, Ye Sun, Xinya Zhang, Xin Sun, Xueping Zhao, Hui Sun, Qimeng Zhang, Guangli Yan, Xijun Wang

PMC · DOI: 10.3389/fendo.2025.1676017 · Frontiers in Endocrinology · 2025-11-03

## TL;DR

This paper explores how disrupted bile acid metabolism contributes to gout and highlights new treatment strategies targeting bile acid pathways.

## Contribution

The paper introduces bile acid metabolism as a novel factor in gout progression and proposes therapeutic strategies targeting bile acid pathways.

## Key findings

- Bile acid imbalances contribute to gout through multiple mechanisms, including urate production and inflammation.
- FXR antagonists and TGR5 agonists are promising therapeutic approaches for gout.
- Probiotics and traditional Chinese medicine may help restore gut microbiota and bile acid synthesis.

## Abstract

Gout, a prevalent metabolic disorder driven by hyperuricemia, results in pathological deposition of monosodium urate (MSU) crystals in joints and soft tissues, stimulating intense inflammatory responses with systemic health consequences. Emerging evidence highlights dysregulated bile acid (BA) metabolism as a pivotal contributor to gout pathogenesis. Imbalances in BA influence disease progression through multiple mechanisms (1): modulating hepatic urate production via PPAR-α/XOD signaling (2), regulating immune responses through FXR/TGR5-dependent suppression of NLRP3 inflammasome activation, and (3) shaping the gut microbiota composition, which reciprocally affects uric acid homeostasis and inflammation. Despite these advances, the precise mechanistic networks linking BA dysmetabolism to gout remain incompletely understood. In this review, we systematically synthesizes current knowledge on BA-gout interactions, elucidated how BA disturbances exacerbate disease progression, discussed the factors contributing to metabolic disorders of BAs, and evaluated promising therapeutic strategies targeting BA pathways. For example, FXR antagonists facilitate the synthesis of BA by inhibiting the aberrant activation of FXR. TGR5 agonists suppress inflammation. Probiotics help restore the diversity of the gut microbiota and increase the abundance of beneficial bacteria, including Bifidobacterium and Lactobacillus. Moreover, traditional Chinese medicine works by improving structural disorders of the gut microbiota and activating CYP7A1 to enhance the BA synthesis pathway. By integrating metabolic, immunological, and microbial perspectives, this work provides a framework for developing novel, mechanism-based interventions against gout.

## Linked entities

- **Genes:** PPARA (peroxisome proliferator activated receptor alpha) [NCBI Gene 5465], xod (xanthine oxidase) [NCBI Gene 117235], NR1H4 (nuclear receptor subfamily 1 group H member 4) [NCBI Gene 9971], GPBAR1 (G protein-coupled bile acid receptor 1) [NCBI Gene 151306], NLRP3 (NLR family pyrin domain containing 3) [NCBI Gene 114548], CYP7A1 (cytochrome P450 family 7 subfamily A member 1) [NCBI Gene 1581]
- **Diseases:** gout (MONDO:0005393)
- **Species:** Bifidobacterium (taxon 1678), Lactobacillus (taxon 1578)

## Full-text entities

- **Genes:** CYP7A1 (cytochrome P450 family 7 subfamily A member 1) [NCBI Gene 1581] {aka CP7A, CYP7, CYPVII}, NR1H4 (nuclear receptor subfamily 1 group H member 4) [NCBI Gene 9971] {aka BAR, FXR, HRR-1, HRR1, PFIC5, RIP14}, NLRP3 (NLR family pyrin domain containing 3) [NCBI Gene 114548] {aka AGTAVPRL, AII, AVP, C1orf7, CIAS1, CLR1.1}, PPARA (peroxisome proliferator activated receptor alpha) [NCBI Gene 5465] {aka NR1C1, PPAR, PPAR-alpha, PPARalpha, hPPAR}, GPBAR1 (G protein-coupled bile acid receptor 1) [NCBI Gene 151306] {aka BG37, GPCR19, GPR131, M-BAR, TGR5}
- **Diseases:** inflammation (MESH:D007249), metabolic disorder (MESH:D008659), hyperuricemia (MESH:D033461), Gout (MESH:D006073)
- **Chemicals:** MSU (MESH:D014527), BAs (MESH:D001464), XOD (-), BA (MESH:D001647)
- **Species:** Lactobacillus (genus) [taxon 1578], Bifidobacterium (genus) [taxon 1678]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12620201/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12620201/full.md

## References

142 references — full list in the complete paper: https://tomesphere.com/paper/PMC12620201/full.md

---
Source: https://tomesphere.com/paper/PMC12620201